Signaling through CD80: An approach for treating lymphomas

Expert Opinion on Therapeutic Targets

Volumn 12, Issue 8, 2008, Pages 969-979

  Mir, Manzoor A ^a   Agrewala, Javed N ^a  

^a INSTITUTE OF MICROBIAL TECHNOLOGY   (India)

Author keywords

Cancer; CD80; Costimulation; Immunotherapy; Lymphomas; Vaccine

Indexed keywords

ADENOVIRUS VECTOR; ALEMTUZUMAB; ANTINEOPLASTIC AGENT; B7 ANTIGEN; BEVACIZUMAB; CANCER VACCINE; CASPASE 8; CD28 ANTIGEN; CD86 ANTIGEN; CETUXIMAB; CYTOKINE; DOXORUBICIN; FLUDARABINE; GALIXIMAB; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 7; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MELPHALAN; MITOMYCIN C; MONOCLONAL ANTIBODY; PLACEBO; PROTEIN BAX; RITUXIMAB; STAPHYLOCOCCUS ENTEROTOXIN A; STREPTAVIDIN; TRASTUZUMAB;

ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; B CELL LYMPHOMA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CD8+ T LYMPHOCYTE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CYTOKINE PRODUCTION; CYTOPENIA; CYTOTOXIC T LYMPHOCYTE; DEEP VEIN THROMBOSIS; DOWN REGULATION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG POTENTIATION; DRUG SAFETY; DRUG SPECIFICITY; DRUG TARGETING; DYSGEUSIA; DYSPEPSIA; FATIGUE; FOLLICULAR LYMPHOMA; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; HUMAN; IMMUNOGENICITY; IMMUNOMODULATION; IMMUNOSURVEILLANCE; KIDNEY CARCINOMA; LOOSE FECES; LYMPH NODE METASTASIS; LYMPH NODE PAIN; LYMPHOMA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYELOMA; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NAUSEA; NONHODGKIN LYMPHOMA; NONHUMAN; OPPORTUNISTIC INFECTION; PAIN; PANCREAS CANCER; PROTEIN EXPRESSION; PSORIASIS; REVIEW; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; TUMOR IMMUNITY; UPREGULATION; VIRAL GENE DELIVERY SYSTEM; VOMITING;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HUMANS; LYMPHOMA; OLIGOPEPTIDES; SIGNAL TRANSDUCTION;

EID: 48449102012     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.12.8.969     Document Type: Review

References (80)

1. Kamangar F, Dores GM, Anderson W. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006;24:2137-50
2. Chambers CA. The expanding world of co-stimulation: the two-signal model revisited. Trends Immunol 2001;22:217-23
3. Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000;192:1027-34
4. Jenkins MK. The role of cell division in the induction of clonal anergy. Immunol Today 1992;13:69-73
5. Frauwirth KA, Thompson CB. Activation and inhibition of lymphocytes by costimulation. J Clin Invest 2002;109:295-309
6. Manzoor A Mir, Javed N Agrewala. Influence of CD80 and CD86 co-stimulation in the modulation of the activation of antigen presenting cells. Curr Immunol Rev 2007;3:160-9
7. Grohmann U, Orabona C, Fallarino F, et al. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol 2002;3:1097-101
8. Puccetti P, Grohmann U. IDO and regulatory T cells: a role for reverse signalling and non-canonical NFκB activation [review]. Nat Rev Immunol 2007;7:817-23
9. Orabona C, Belladonna ML, Vacca C, et al. Cutting edge: silencing suppressor of cytokine signaling 3 expression in dendritic cells turns CD28-Ig from immune adjuvant to suppressant. J Immunol 2005;174:6582-6
10. Yee KW, O'Brien SM. Emerging drugs for chronic lymphocytic leukaemia. Expert Opin Emerging Drugs 2006;11:167-89
11. Suvas S, Singh V, Sahdev S, et al. Distinct role of CD80 and CD86 in the regulation of the activation of B cell and B cell lymphoma. J Biol Chem 2002;277:7766-75
12. Hirokawa M, Kuroki J, Kitabayashi A, Miura AB. Transmembrane signaling through CD80 B7-1 induces growth arrest and cell spreading of human B lymphocytes accompanied by protein tyrosine phosphorylation. Immunol Lett 1996;50:95-8
13. Czuczman MS, Thall A, Witzig TE, et al. Phase I/II study of galiximab, an antt-CD80 antibody, for relapsed or refractory follicular lymphoma. J Clin Oncol 2005;23:4390-8
14. Leonard J, Friedberg J, Younes A, et al. A phase I/II study of galiximab an anti-CD80 monoclonal antibody in combination with rituximab for relapsed or refractory, follicular lymphoma. Ann Oncol 2007;29. Ann Oncol 2007;18:1216-23
15. Wang S, Chen L. Co-signaling molecules of the B7-CD28 family in positive and negative regulation of T lymphocyte responses. Microbes Infect 2004;6:759-66
16. Zheng P, Sarma S, Guo Y, Liu Y. Two mechanisms for tumor evasion of preexisting cytotoxic T-cell responses: lessons from recurrent tumors. Cancer Res 1999;59:3461-7
17. Matulonis UA, Dosiou C, Lamont C, et al. Role of B7-1 in mediating an immune response to myeloid leukemia cells. Blood 1995;85:2507-15
18. Ramarathinam L, Castle M, WU Y, Liu Y. T cell costimulation by B7/BB1 induces CD8 T cell-dependent tumor rejection: an important role of B7/ BB1 in the induction, recruitment, and effector function of antitumor T cells. J Exp Med 1994;179:1205-14
19. Huang AY, Bruce AT, Pardoll DM, Levitsky HI. Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo? J Exp Med 1996;183:769-76
20. WU TC, Huang AY, Jaffee EM, et al. A reassessment of the role of B7-1 expression in tumor rejection. J Exp Med 1995;182:1415-21
21. Xia D, Hao S, Xiang J. CD8+ cytotoxic T-APC stimulate central memory CD8+ T cell responses via acquired peptide-MHC class I complexes and CD80 costimulation, and IL-2 secretion. J Immunol 2006;177:2976-84
22. Suresh M, Whitmire JK, Harrington LE, et al. Role of CD28-B7 interactions in generation and maintenance of CD8 T cell memory. J Immunol 2001;167:5565-73
23. Matsumoto K, Anasetti C. The role of T cell costimulation by CD80 in the initiation and maintenance of the immune response to human leukemia. Leuk Lymphoma 1999;35:427-35
24. Gajewski TF. B7-1 but not B7-2 efficiently costimulates CD8+ T lymphocytes in the P815 tumor system in vitro. J Immunol 1996;156:465-72
25. La Motte RN, Sharpe AH, Bluestone JA, Mokyr MB. Importance of B7-1-expressing host antigen-presenting cells for the eradication of B7-2 transfected P815 tumor cells. J Immunol 1998;161:6552-8
26. Boussiotis VA, Freeman GJ, Gray G, et al. B7 but not intercellular adhesion molecule-1 costimulation prevents the induction of human alloantigen-specific tolerance. J Exp Med 1993;178:1753-63
27. Reiser H, Freeman GJ, Razi-Wolf Z, et al. Murine B7 antigen provides an efficient costimulatory signal for activation of murine T lymphocytes via the T-cell receptor/CD3 complex. Proc Natl Acad Sci USA 1992;89:271-5
28. Harding FA, Allison JP CD28-B7 interactions allow the induction of CD8+ cytotoxic T lymphocytes in the absence of exogenous help. J Exp Med 1993;177:1791-6
29. Chen L, Linsley PS, Hellstrom KE. Costimulation of T cells for tumor immunity. Immunol Today 1993;14:483-6
30. Townsend SE, Allison JP. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science 1993;259:368-70
31. Tirapu I, Huarte E, Guiducci C, et al. Low surface expression of B7-1 CD80 is an immunoescape mechanism of colon carcinoma. Cancer Res 2006;66:2442-50
32. Kelly JM, Takeda K, Darcy PK, et al. A role for IFN-γ in primary and secondary immunity generated by NK cell-sensitive tumor-expressing CD80 in vivo. J Immunol 2002;168:4472-9
33. Chambers BJ, Salcedo M, Ljunggren HG. Triggering of natural killer cells by the costimulatory molecule CD80 B7-1. Immunity 1996;5:311-7
34. Gao JX, Liu X, Wen J, et al. Two-signal requirement for activation and effector function of natural killer cell response to allogeneic tumor cells. Blood 2003;102:4456-63
35. Heise CP, Shi F, Albertini MR, Mahvi DM. B7.1 expression eliminates tumor resistance to IL-12 gene therapy. Cancer Gene Ther 2001;8:118-27
36. Geldhof AB, Raes G, Bakkus M, et al. Expression of B7-1 by highly metastatic mouse T lymphomas induces optimal natural killer cell-mediated cytotoxicity. Cancer Res 1995;55:2730-3
37. Chen L, Ashe S, Brady WA, et al. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 1992;71:1093-102
38. Baskar S, Ostrand-Rosenberg S, Nabavi N, et al. Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules. Proc Natl Acad Sci USA 1993;90:5687-90
39. Sakate Y, Yashiro M, Tanaka H, et al. Usefulness of inhibiting the lymph node metastasis in human gastric carcinoma by B71 gene transfection. J Surg Res 2004;122:89-95
40. Yu X, Abe R, Hodes RJ. The role of B7-CD28 co-stimulation in tumor rejection. Int Immunol 1998;10:791-7
41. Bai XF, Liu J, May KF Jr, et al. B7-CTLA4 interaction promotes cognate destruction of tumor cells by cytotoxic T lymphocytes in vivo. Blood 2002;99:2880-9
42. Dohring C, Angman L, Spagnoli G, Lanzavecchia A. T-helper- and accessory-cell-independent cytotoxic responses to human tumor cells transfected with a B7 retroviral vector. Int J Cancer 1994;57:754-9
43. Sule-Suso J, Arienti F, Melani C, et al. A B7-1-transfected human melanoma line stimulates proliferation and cytotoxicity of autologous and allogeneic lymphocytes. Eur J Immunol 1995;25:2737-42
44. + immunoregulatory T cells that control autoimmune diabetes. Immunity 2000; 12:431-40
45. Sojka DK, Donepudi M, Bluestone JA, Mokyr MB. Melphalan and other anticancer modalities up-regulate B7-1 gene expression in tumor cells. J Immunol 2000;164:6230-6
46. Lohr J, Knoechel B, Jiang S, et al. The inhibitory function of B7 costimulators in T cell responses to foreign and self-antigens. Nat Immunol 2003;4:664-9
47. Abbas AK, Sharpe AH. Dendritic cells giveth and taketh away. Nat Immunol 2005;6:227-8
48. Singh NP, Miller RW, Yolcu ES, et al. Primary tumor cells resected from cancer patients and decorated with a novel form of CD80 protein serve as effective antigen-presenting cells for the induction of autologous T cell immune responses ex vivo. Hum Gene Ther 2006;17:334-46
49. Liu J, Xia X, Torrero M, et al. The mechanism of exogenous B7.1-enhanced IL-12-mediated complete regression of tumors by a single electroporation delivery. Int J Cancer 2006;119:2113-8
50. Putzer BM, Rodicker F, Hitt MM, et al. Improved treatment of pancreatic cancer by IL-12 and B7.1 costimulation: antitumor efficacy and immunoregulation in a nonimmunogenic tumor model. Mol Ther 2002;5:405-12
51. Cayeux S, Beck C, Aicher A, et al. Tumor cells cotransfected with interleukin-7 and B7.1 genes induce CD25 and CD28 on tumor-infiltrating T lymphocytes and are strong vaccines. Eur J Immunol 1995;25:2325-31
52. Si SY, Hu PZ, Huang YY, et al. Tumor cells with B7.1 and transmembrane anchored staphylococcal enterotoxin A generate effective antitumor immunity. Biochem Biophys Res Commun 2006;347:208-14
53. Van Ginderachter JA, Liu Y, Geldhof AB, et al. B7-1, IFNγ and anti-CTLA-4 co-operate to prevent T-cell tolerization during immunotherapy against a murine T-lymphoma. Int J Cancer 2000;87:539-47
54. Baskar S, Glimcher L, Nabavi N, et al. Major histocompatibility complex class II+B7-1+ tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice. J Exp Med 1995;181:619-29
55. Ke X, Jia L, Wang J, Wang D. Transfection of B7-1 cDNA empowers antigen presentation of blood malignant cells for activation of anti-tumor T cells. Chin Med J Engl 2003;116:78-84
56. Chan L, Hardwick N, Darling D, et al. IL-2/B7.1 CD80 fusagene transduction of AML blasts by a self-inactivating lentiviral vector stimulates T cell responses in vitro: a strategy to generate whole cell vaccines for AML. Mol Ther 2005;11:120-31
57. Antonia Sj, Seigne J, Diaz J, et al. Phase I trial of a B7-1 CD80 gene modified autologous tumor cell vaccine in combination with systemic interleukin-2 in patients with metastatic renal cell carcinoma. J Urol 2002;167:1995-2000
58. Wen XY, Mandelbaum S, Li ZH, et al. Tricistronic viral vectors co-expressing interleukin-12 (IL-12) and CD80 (B7-1) for the immunotherapy of cancer: preclinical studies in myeloma. Cancer Gene Ther 2001;8:361-70
59. Carlring J, Shaif-Muthana M, Sisley K, et al. Apoptotic cell death in conjunction with CD80 costimulation confers uveal melanoma cells with the ability to induce immune responses. Immunology 2003;109:41-8
60. Racke Mm, Mosior M, Kovacevic S. Activation of caspase-3 alone is insufficient for apoptotic morphological changes in human neuroblastoma cells. J Neurochem 2002;80:1039-48
61. Ruiz-Ruiz C, Munoz-Pinedo C, Lopez-Rivas A. Interferon-γ treatment elevates caspase-8 expression and sensitizes human breast tumor cells to a death receptor-induced mitochondria-operated apoptotic program. Cancer Res 2000;60:5673-80
62. Waterhouse P, Penninger JM, Timms E, et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 1995;270:985-8
63. Bogner C, Sandherr M, Perker M, et al. Cyclin E but not bcl-2, bax or mcl-1 is differentially expressed in ZAP 70-positive and ZAP 70-negative B-CLL cells. Ann Hematol 2006;85:458-62
64. Logue EC, Sha WC. CD28-B7 bidirectional signaling: a two-way street to activation. Nat Immunol 2004;5:1103-5
65. Orabona C, Grohmann U, Belladonna ML, et al. CD28 induces immuno-stimulatory signals in dendritic cells via CD80 and CD86. Nat Immunol 2004;5:1134-42
66. Harris M. Monoclonal antibodies as therapeutic agents for cancer [review]. Lancet Oncol 2004;5(5):292-302
67. Keating M, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (campath H1) in patients who have failed fludarabine: results of a large international study. Blood 2002;99:3554-61
68. Hurwitz H, Fehrenbacher L, Cartwright T, et al. Bevacizumab a monoclonal antibody to vascular-endothelial growth factor prolongs survival in first-line colorectal cancer: results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5 fluorouracil, leucovorin) as first-line therapy in subjects with metastatic colorectal cancer [abstract 3646]. Proc Am Soc Clin Oncol 2003;22
69. Plosker GL, Figgitt DP. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia [review]. Drugs 2003;63:803-43
70. Demidem A, Lam T, Alas S, et al. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 1997;12:177-85
71. Davis TA, Grillo-López AJ, White CA, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 2000;18:3135-43
72. IDEC Pharmaceuticals. Rituxan (rituximab) package insert. San Diego, CA, IDEC Pharmaceuticals Corporation; 2002
73. Lyman GH, Delgado DJ. Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma. Cancer 2003;98:2402-9
74. Genentech, Inc. Herceptin (trastuzumab) package insert. South San Francisco, CA, Genentech, Inc.; 2003
75. Bajorath J, Peach RJ, Linsley PS. Immunoglobulin fold characteristics of B7-1 CD80 and B7-2 CD86. Protein Sci 1994;3:2148-50
76. Mavromatis BH, Cheson BD. Novel therapies for chronic lymphocytic leukemia. Blood Rev 2004;18:137-48
77. Czuczman MS. Anti-CD80 monoclonal antibody: galiximab. Haematol Rep 2005;36:35-6
78. Gottlieb AB, Kang S, Linden KG, et al. Evaluation of safety and clinical activity of multiple doses of the anti-CD80 monoclonal antibody, galiximab, in patients with moderate to severe plaque psoriasis. Clin Immunol 2004;111:28-37
79. Hariharan HK, Murphy T, Clanton D, et al. Combining galiximab with the chemotherapeutic agents fludarabine or doxorubicin improves efficacy in animal models of lymphoma. ASCO Annual Meeting Proceedings. J Clin Oncol 2007;3:3040
80. Gordon LI, Moore JO, Cheson BD, et al. Phase I results from a multicenter trial of galiximab (anti-CD80 antibody, IDEC-114) in combination with rituximab for the treatment of follicular lymphoma [abstract 4951]. Blood 2003;102:307b